Core Viewpoint - The article discusses the upcoming large-scale procurement project for hemostatic materials in the Beijing-Tianjin-Hebei region, highlighting the increasing demand for domestic absorbable hemostatic materials and the role of companies like Maipu Medical in standardizing these products [2][15]. Group 1: Procurement Details - The procurement will include various hemostatic materials such as gauze, hemostatic powder, collagen sponge, and more [2]. - Public medical institutions are required to participate, while other social medical institutions can join voluntarily based on regional regulations [3]. - The demand for these materials must be reported for the upcoming year, detailing specific products [4]. Group 2: Industry Trends - The demand for hemostatic materials is rising due to the trend towards minimally invasive and precise surgical procedures, which traditional methods cannot adequately support [6]. - The market for absorbable regenerated cellulose has been dominated by imported brands due to technological barriers in domestic production [7]. Group 3: Company Initiatives - Maipu Medical has been a pioneer in developing domestic absorbable hemostatic materials, introducing the "Jisuting®" product, which fills a technological gap in the market [8]. - The company has led the drafting of the first group standard for absorbable regenerated cellulose in China, establishing a unified testing framework for product quality [10][11]. - This standardization is expected to enhance the consistency and safety of domestic hemostatic materials in clinical applications [12]. Group 4: Product Features and Certifications - The "Jisuting®" product utilizes non-woven technology, offering a larger surface area for better blood contact efficiency and can be shaped for various surgical needs [13]. - It is the only domestic product in the current procurement project that is a three-class implantable regenerated cellulose with both NMPA and CE certifications, having been validated in over 600,000 clinical cases globally [14]. Group 5: Market Impact - The initiation of the Beijing-Tianjin-Hebei "3+N" alliance procurement is expected to accelerate the structural adjustment of the hemostatic materials market [15]. - This procurement round is anticipated to facilitate the entry of domestic materials into high-end surgical supply chains, transitioning from "substitutable" to "high-quality application" [16]. - Future products that are compliant, stable, and supported by sufficient clinical data will likely gain trust from medical institutions and practitioners [17].